Skip to main content
Premium Trial:

Request an Annual Quote

RenalytixAI, DaVita to Offer Chronic Kidney Disease Risk Assessment, Patient Management

NEW YORK – Startup RenalytixAI said on Tuesday that it has partnered with DaVita to slow disease progression and improve health outcomes for US patients with early-stage kidney disease through risk assessments and end-to-end care management.

Aiming to launch the collaboration in three major markets later this year, the partners will pursue risk-sharing arrangements with healthcare providers and payors to drive kidney disease patient care innovation and cost efficiencies, as well as improve quality of life.

The team will use RenalytixAI's KidneyIntelX in vitro diagnostic platform, which applies a machine learning algorithm to assess a combination of biomarkers from a patient's blood sample and information from their electronic health records to create a personalized risk score. The firms believe the program may also help minimize kidney disease misclassification and expand indicated use claims for KidneyIntelX.

After risk stratification, patients identified as intermediate- and high-risk will receive care management support through DaVita's integrated kidney care program. RenalytixAI will compensate DaVita in lieu of providing those services itself.

"Almost 50 percent of people whose kidneys fail find out after it is too late, and we are on a mission to change that," Javier Rodriguez, CEO of DaVita, said in a statement. "Our partnership with RenalytixAI could allow us to help slow disease progression for the millions of people living with kidney disease."

Financial details of the agreement were not disclosed.

"This is the first clinical-grade program that delivers advanced earl-stage prognosis and risk stratification, combined with actionable care management right to the primary care level, where the majority of kidney patients are being seen," James McCullough, CEO of RenalytixAI, added. "Making fundamental change in kidney disease health economics and outcomes must begin with providing a clear, actionable understanding of disease progression risk."